Can You Catch Alzheimer’s Before It Starts?

Topol stresses the test has been available commercially in the U.S. for two years but is virtually unknown. A randomized trial presented at the American Academy of Neurology showed that in people with elevated p-tau217, a lifestyle intervention drove the marker down by up to 75%, much like lowering LDL cholesterol. He positions this as the centerpiece of a new ‘know it and beat it’ strategy, where you establish baseline risk, monitor with brain organ clocks and other proteomics, and aggressively deploy lifestyle (diet, exercise, sleep, social connection) to bring the number down. He predicts that within a few years add-on GLP-1 drugs or other anti-inflammatory agents could amplify the effect.

Topol, a cardiologist who historically emphasized aerobic exercise, changed his practice after reviewing the literature for his book. He notes that many patients who only do cardio miss the profound metabolic and anti-inflammatory benefits of resistance work. He also connects this to the protein debate: people foolishly try to build muscle by eating massive protein without adequate strength stimulus. He observes that many super-agers in the Wellderly study stayed physically active, not sedentary. He describes his personal transformation — from a thin runner to being stronger than ever without extreme protein — as a proof of concept that even late adoption works.

Topol references his friend Chris Van Tulleken’s 30-day UPF diet experiment. Van Tulleken, a UK physician-scientist, underwent brain scans and inflammatory biomarker testing before and after. Within 30 days his brain was inflamed, all inflammation markers were abnormally elevated, and he gained 20 pounds — a dramatic demonstration of acute harm. Topol calls UPF ‘horrendous’ and notes that while some nations are taking action, the U.S. has done nothing. He also ties this to the sugar–Alzheimer’s link, citing the ‘type 3 diabetes’ concept. In a 30-year study of 105,000 people, only 9% reached the ‘elderly’ state past age 70 without disease; those 9% ate predominantly plant-based diets with limited red meat.

Topol devotes substantial discussion to debunking the protein craze. He notes that many high-profile advocates push 1–2 grams per pound, which translates to >2.2–4.4 g/kg — levels he says are unsupported and dangerous. He has spoken with patients who follow this advice and tries to convert them with data. He acknowledges that anabolic resistance in older adults is real, but argues that the solution is a small increase to 1.2–1.4 g/kg, combined with heavy resistance training, not extreme protein loading. He also references that the protein researchers themselves (like Don Layman) debate this, but Topol sides with the conservative numbers and warns that the average American already gets excessive animal protein, contributing to the cardiometabolic epidemic.

Topol is deeply critical of current screening dogma. He explains that simple polygenic scores and whole-genome sequencing (now about $200) can stratify people into low, medium, and high risk for specific cancers. For those at high risk, a plasma tumor DNA test becomes much more informative. He describes the Johns Hopkins effort combining protein markers with gene variants to create an inexpensive blood test, and the VA/Denmark AI study that spotted pancreatic cancer from routine labs trending within normal limits. He argues that we have all the tools — AI, proteomics, liquid biopsies, genomic risk — to make cancer dying a ‘historical footnote.’ He also highlights the immune surveillance angle: some positive liquid biopsies clear on repeat testing, suggesting the person’s immune system extinguished the nascent cancer; we need a clinical immune metric to identify those with failing surveillance. He holds up AI mammograms, which in a Swedish trial of >100,000 women detected 25% more cancers with no increase in false positives and could predict cancer 5 years in advance — yet they are not deployed in the US.

Topol describes how the old methylation clocks gave a single ‘biologic age’ number based on white blood cell DNA, which was indirect and expensive. The proteomic organ clocks use up to 11,000 proteins and already cost under $100 in research settings; he expects them to become routine. He highlights that the UK Biobank is deploying this at scale ($50 per person) on 500,000 people. He sees them as the missing piece that finally gives a temporal map — which organ, how fast, and when to act — for the 20-year lead time of the three major diseases. Combined with polygenic scores and other markers, they create a full-stack assessment.

Topol explains that p-tau217 is the earliest biomarker to rise, starting two decades before mild cognitive impairment and a few additional years before actual Alzheimer’s dementia. A randomized trial presented at the Academy of Neurology showed that a lifestyle intervention reduced p-tau217 (and p-tau181) by up to 75%. He argues this is analogous to LDL cholesterol: you can measure it, track it, and bring it down with aggressive lifestyle changes. He stresses that the test should only be used in people with elevated genetic risk (APOE4 carrier or polygenic risk) or family history, because in low-risk groups false positives can lead to premature ‘stage 1 Alzheimer’s’ labeling, a problem he attributes to the Alzheimer’s Association. He also notes that future GLP-1 drug trials are testing whether reducing brain inflammation can further lower risk.

Topol describes that the protein-based organ clocks are generated by AI analysis of the plasma proteome, which tags proteins to specific organs. The UK Biobank is already running this at $50 per sample on 500,000 people. He emphasizes that this is a breakthrough because it tells not only which organ is aging out of sync but also when disease is likely to manifest — closing the decades-long runway we previously could not leverage. Combined with polygenic risk scores and other markers, the organ clocks give a multi-layered, precision-prevention stack. He notes that this technology could soon become part of routine annual checkups, finally delivering on the promise of primary prevention.

Topol recounts the seven-year effort to recruit this unique cohort. Nearly all had led physically active, socially engaged lives with an upbeat disposition — they were ‘relatively thin’ and avoided obesity. Yet interestingly, some outliers existed: a 99-year-old lifelong two-pack-a-day smoker made it into the group, suggesting that immune resilience or stochastic factors also matter. The finding that polygenic risk loads can be neutralized by lifestyle behaviors is reinforced by separate studies he reviews in his book. He calls the result ‘liberating’ even for himself, given his own poor family history. He further speculates that the immune system — still not clinically measureable in a granular way — may be the hidden key to surviving into advanced age without disease.

Topol describes how the plaques containing plastic were grossly inflamed under the microscope; there appeared to be a dose-response relationship. He ties this to the broader failure to address air pollution and forever chemicals, noting that fine particulate matter (PM2.5) likewise provokes systemic inflammation that contributes to all three big diseases. He and the host agree that detoxification support and individual avoidance — like never microwaving food in plastic — are actionable, but systemic change is needed. This finding, he says, demands that modern cardiology broaden its lens to include environmental plastic burden as a modifiable contributor.

Topol reviewed multiple studies showing that excess animal protein is pro-inflammatory and atherogenic. He notes that some protein researchers like Don Layman advocate higher intakes to overcome anabolic resistance in older adults, but he argues the evidence does not support exceeding 1.6 g/kg. He personally advocates for 1.2–1.4 g/kg, and emphasizes that strength training — not just protein — is the critical lever for maintaining muscle mass. He worries that people are being told dangerous levels, and that the focus on protein distracts from more powerful interventions like resistance exercise. He also notes that the US diet already has excessive animal protein intertwined with ultraprocessed foods.

Topol explains that deep slow-wave sleep is the period when the brain clears beta-amyloid and tau waste products. His own deep-sleep tracking revealed he was getting less than 15 minutes per night. Through careful habit adjustments (timing of meals, exercise, fluid intake, stress management) he raised it to 45–60 minutes. He warns that zolpidem-type drugs not only fail to facilitate this clearance but actively worsen the accumulation, so patients may sleep longer but not reap neuroprotective benefits. Combined with the strong epidemiologic data linking insufficient deep sleep to dementia, he frames sleep as a ‘drug’ more powerful than any pharmacologic agent.